.

Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chubb
Citi
Julphar
Covington
Medtronic
Novartis
UBS
Johnson and Johnson
Merck
Cipla

Generated: November 19, 2017

DrugPatentWatch Database Preview

Claims for Patent: 7,291,347

« Back to Dashboard

Claims for Patent: 7,291,347

Title:Succinate salt of O-desmethyl-venlafaxine
Abstract:A novel salt of O-desmethyl venlafaxine is provided, O-desmethylvenlafaxine succinate. Pharmaceutical compositions, dosage forms and methods of use are also provided.
Inventor(s): Hadfield; Anthony Francis (Nanuet, NY), Shah; Syed Muzafar (East Hanover, NJ), Provost; James Andrew (Waltham Chase, GB)
Assignee: Wyeth (Five Giralda Farms, Madison, NJ)
Application Number:11/334,223
Patent Claims: 1. An oral dosage form comprising O-desmethyl venlafaxine succinate, wherein the oral dosage form is a tablet.

2. An oral dosage form comprising O-desmethyl venlafaxine succinate, wherein the oral dosage form is a capsule.

3. The oral dosage form of claim 1 or 2, wherein the oral dosage form comprises from about 30% to about 50% by weight of O-desmethyl venlafaxine succinate.

4. The oral dosage form of claim 1 or 2, wherein the oral dosage form comprises from about 32% to about 44% by weight of O-desmethyl venlafaxine succinate.

5. The oral dosage form of claim 1 or 2, wherein the oral dosage form comprises about 50% by weight of O-desmethyl venlafaxine succinate.

6. The oral dosage form of claim 1 or 2, wherein the oral dosage form comprises about 44% by weight of O-desmethyl venlafaxine succinate.

7. The dosage form of claim 1 or 2, wherein each dosage form contains from about 15 mg to about 350 mg of O-desmethyl venlafaxine succinate.

8. The dosage form of claim 1 or 2, wherein each dosage form contains from about 10 mg to about 1000 mg of O-desmethyl venlafaxine succinate.

9. The dosage form of claim 1 or 2, wherein each dosage form contains 200 mg of O-desmethyl venlafaxine succinate.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Covington
Queensland Health
Argus Health
Merck
Moodys
Daiichi Sankyo
Novartis
US Army
Julphar
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot